This week, global pharmaceutical manufacturer Boehringer Ingelheim announced a collaboration with BERG. BERG is a clinical-stage biology company which utilizes AI to map diseases and revolutionize treatments across neurology, rare diseases, and cancer. BERG identifies clinical biomarkers to accelerate the discovery and development pathway.
The goal for this collaboration is to better understand the spectrum of inflammatory diseases and their biological drivers. BERG is also not new to collaborating with pharmaceutical companies. The company brings with it extensive IP in the AI biotech sector, focusing mostly on molecular diagnostic tools. One of their most recent granted patents teaches a Bayesian network model for healthcare diagnostics.
Last month, Boehringer Ingelheim announced a partnership with Insilico Medicine, also for AI-based drug development. Unlike BERG, Insilico Medicine's focus is on areas including heart failure, cystic fibrosis, and muscular dystrophy.
